← Back to signals
NBIX
BUYNeurocrine Biosciences Inc.
Health Care
0.97
PEGY ratio
Rank #171
Why This Matters
This stock appears undervalued relative to its growth and dividend yield. Strong projected growth of 95.2% annually over 5 years.
NBIX trades at 24.3x earnings against 25.0% capped growth (actual 95.2%) (no dividend) (PEGY 0.97). Valuation looks favorable — the price is not fully reflecting the growth and yield on offer.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 95.2%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-05-29
Valuation
24.3x
P/E Ratio
Growth
95.2%
5yr EPS
Income
0.0%
Div Yield
PEGY Components
PEGY Score0.97
Denominator25.0%
EPS (TTM)$6.51
Market Data
Price$158.30
ExchangeNASDAQ
S&P 500
What Changed
PEGY Score
0.96→0.97(+0.01)
Rank
#168→#171(3 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only